乐观
$539.08
情景价格
$690.000
-6.417 (-0.93%)收盘时
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies.
Thermo Fisher Scientific Inc is a good buy right now, with a current price of $690 and a forward P/E ratio of 24.15, indicating reasonable valuation compared to its growth prospects. The stock has shown a 5-day change of +4.86% and a year-to-date change of +16.45%, reflecting strong momentum. However, the RSI is at 68.22, suggesting it is nearing overbought territory, which is a risk to consider.
Morgan Stanley
$730
2026-10-12
Morgan Stanley
2026-10-12
目标价
$730
BofA
$745
2026-10-09
BofA
2026-10-09
目标价
$745
Barclays
$750
2026-10-07
Barclays
2026-10-07
目标价
$750
Deutsche Bank
$720
2026-09-25
Deutsche Bank
2026-09-25
目标价
$720
UBS
$730
2026-09-09
UBS
2026-09-09
目标价
$730
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Strong Outlook for Q3 Earnings Season Amid Market Caution

Latest Wall Street Rating Updates

Market Outlook: Tech Stock Dynamics and Investment Opportunities

JPMorgan Updates October Investment Recommendations Amid Mixed Market Performance

West Pharmaceutical Services Stock Recovery
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies. It operates in the Healthcare sector (MEASURING & CONTROLLING DEVICES, NEC industry).
Thermo Fisher Scientific Inc is a good buy right now, with a current price of $690 and a forward P/E ratio of 24.15, indicating reasonable valuation compared to its growth prospects. The stock has shown a 5-day change of +4.86% and a year-to-date change of +16.45%, reflecting strong momentum. However, the RSI is at 68.22, suggesting it is nearing overbought territory, which is a risk to consider.
15 analysts cover TMO: 14 rate it Buy, 1 Hold and 0 Sell. The average price target is 658.89.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。